Analysis of preoperative concurrent chemoradiotherapy in the treatment of patients with superior sulcus tumor of the lung / 中国肺癌杂志

<p><b>BACKGROUND</b>Recently chemoradiotherapy becomes a standard treatment for un- resectable advanced non-small cell lung cancer (NSCLC) instead of radiotherapy alone. Superior sulcus tumor of the lung (Pancoast tumor) is a clinical subtype of NSCLC. The aim of this study is to compare the clinical effects and toxicities of preoperative concurrent chemoradiotherapy with radiotherapy alone in patients with superior sulcus tumors.</p><p><b>METHODS</b>Fifty-six patients with superior sulcus tumors were divided randomly into two groups: twenty-six patients received concurrent chemoradiotherapy (chemoradiotherapy group), the other thirty patients received only radiotherapy (radiotherapy group). For both groups, the same radiation technic was given with the convention fraction. The total dose was 45Gy/25 fraction/5 weeks. For the chemoradiotherapy group, the patients were also given with concurrent chemotherapy (navelbine 15-18mg/m² on the 1st and 8th day, cisplatin 60mg/m² on the 1st day).</p><p><b>RESULTS</b>The rate of complete resection in the chemoradiotherapy group was significantly higher than that in the radiotherapy group (92.3% vs 80.0%, P < 0.05); The complete pathological response rate and 2-year survival rate in the chemoradiotherapy group were significantly higher than those in the radiotherapy group (P < 0.01, P < 0.01). The incidences of grade III-IV radiation esophagitis and leukopenia in the chemoradiotherapy group were significantly higher than those in the radiotherapy group (23.1% and 23.1% vs 6.7% and 0, P < 0.01, P < 0.01).</p><p><b>CONCLUSIONS</b>Preoperative concurrent chemoradiotherapy has the potential of improving the survival rate of superior sulcus tumors. It can also increase the acute toxic effect, but all patients can tolerate this treatment regimen, so it might be a new "standard treatment" for superior sulcus tumor of the lung.</p>

Angioimmunoblastic T cell lymphoma 14 cases clinical analysis / 肿瘤研究与临床

Objectives To investigate the clinical and pathological characters , treatment of patients with Angioimmunoblastic T cell lymphoma(AITL). Methods From 1997 to 2004, 14 patients with AITL were reviewed retrospectively in our hospital. Results The most common symptoms at the presentation included general lymphadenopathy. 9 patients had fever. 3 patients had autoimmune hemolytic anemia.The histopathologic characteristics of AITL was generalized as:the damage of normal structure of lymphonodus,the proliferation of immunoblastic cell and arborescent supervascularization. All immunophenotyping were T cell type.14 patients were with ProMACE-CytaBOM regimen.The overall response rate was 57% and CR 3 cases, PR 5 cases. Median survival times was 25 months. 2-year survival was 60 %. Conclusions The most cases with AITL runs an aggressive course.The disease may progress rapidly and have unfavorable prognosis. Therefore further studies are repuired to improve the outcome.